Clinical Report: Measles Outbreaks Are a Lab Wake-Up Call
Overview
The ongoing measles outbreaks in the U.S. highlight the need for improved laboratory testing and public health responses. Declining vaccination rates, particularly in certain communities, pose a risk to the country's measles elimination status.
Background
Measles was declared eliminated in the U.S. in 2000, but recent outbreaks have raised concerns about the resurgence of this preventable disease. Factors such as declining vaccination rates, exacerbated by the COVID-19 pandemic and vaccine skepticism, have led to communities with vaccination coverage below 50%. This situation threatens herd immunity and increases the risk of sustained transmission.
Data Highlights
As of January 2025, the U.S. has reported continuous measles cases since January 2025, with outbreaks primarily in under-vaccinated communities.
Key Findings
Vaccination coverage must reach approximately 95% to prevent sustained measles transmission.
Some U.S. communities have MMR vaccination rates below 50%, particularly in Texas, South Carolina, and Utah.
Measles can lead to serious complications, including pneumonia, encephalitis, immune amnesia, and subacute sclerosing panencephalitis (SSPE).
Current testing for measles relies on laboratory-developed tests (LDTs) due to the absence of FDA-cleared assays.
Molecular testing, such as PCR, can detect measles infection earlier than traditional IgM serology, which may yield false negatives.
Laboratories must develop standardized testing protocols and maintain quality assurance for accurate measles diagnosis.
Clinical Implications
Laboratories should establish clear testing plans and collaborate with public health authorities to ensure identification of measles cases. Understanding the limitations of current testing methods is crucial for effective outbreak management.
Conclusion
The resurgence of measles outbreaks necessitates action to improve laboratory testing capabilities and vaccination efforts.
The assay is indicated to identify patients with advanced melanoma who have BRAF V600E or BRAF V600K variants and may benefit from FDA-approved targeted therapies.
